TITLE

Drug Discovery in Ovarian Cancer

AUTHOR(S)
Chase, Dana M.; Mathur, Nidhee; Tewari, Krishnansu S.
PUB. DATE
November 2010
SOURCE
Recent Patents on Anti-Cancer Drug Discovery;Nov2010, Vol. 5 Issue 3, p251
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Drug discovery in the ovarian cancer arena has led to the activation of several important clinical trials. Many biologic agents have come down the pipeline and are being studied in phase II trials for recurrent disease. These agents include antivascular compounds that disrupt angiogenesis through a variety of mechanisms (e.g., prevention of ligandbinding to the vascular endothelial growth factor receptor-2 (VEGF-R2), high-affinity VEGF blockade, oral inhibitors of tyrosine kinases stimulated by VEGF, inhibition of α5β1 integrin, neutralization of angioproteins, etc.). Other novel drugs include oral platinum compounds as well as those that antagonize the tumor proliferation genes in the Hedgehog pathway, and that target folic acid receptors which are expressed by ovarian cancer cells. In addition, studies are underway with oral agents that inhibit the tyrosine kinase activity associated with two oncogenes (epidermal growth factor receptor (EGFR) and HER-2/neu). Finally, emerging technologies in clinical trials include nanotechnology to enhance delivery of chemotherapy to ovarian tumors, drug resistance/sensitivity assays to guide therapy, and agents that mobilize and induce proliferation of hematopoetic progenitor cells to aid in red blood cell, white blood cell, and platelet recovery following chemotherapy. The relevant patents in drug discovery of ovarian cancer are discussed.
ACCESSION #
64365023

 

Related Articles

  • New therapeutic strategy discovered for ovarian cancer.  // Oncology Nurse Advisor;May/Jun2015, Vol. 6 Issue 3, p11 

    No abstract available.

  • Trabectedin in ovarian cancer: could we expect more? Sessa, C.; D'Incalci, M. // Annals of Oncology;Jan2011, Vol. 22 Issue 1, p7 

    No abstract available.

  • Challenges of Cancer Drug Design A Drug Metabolism Perspective. Sanchez, R.I.; Mesia-Vela, S.; Kauffman, F.C. // Current Cancer Drug Targets;May2001, Vol. 1 Issue 1, p1 

    The time course and duration of action of drugs used in cancer chemotherapy are greatly influenced by the molecular and biochemical properties of enzymes associated with their metabolism. Variation in the response of individual patients to cancer chemotherapeutic agents is in large measure due...

  • Potential Application of Peptides in Tumor Targeting and Anticancer Therapeutics. Prakash, Jai // Current Pharmaceutical Biotechnology;Aug2011, Vol. 12 Issue 8, p1087 

    No abstract available.

  • Recent Progress in the Development of Anticancer Agents. Sandor Eckhardt // Current Medicinal Chemistry - Anti-Cancer Agents;May2002, Vol. 2 Issue 3, p419 

    Cancer chemotherapy started with the discovery of the cytostatic effect of N-mustard and its derivatives more than five decades ago. This observation opened the way for the synthesis of various alkylating agents, antimetabolites and antimitotics expliciting antitumour activity against several...

  • Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Baek, J. H.; Kim, J. G.; Jeon, S. B.; Chae, Y. S.; Kim, D. H.; Sohn, S. K.; Lee, K. B.; Choi, Y. J.; Shin, H. J.; Chung, J. S.; Cho, G. J.; Jung, H. Y.; Yu, W. // British Journal of Cancer;5/22/2006, Vol. 94 Issue 10, p1407 

    The present study was conducted to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received oral capecitabine 1000 mg m(-2)...

  • Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma. Ishikawa, Toru; Ohwada, Susumu // World Journal of Gastroenterology;5/14/2008, Vol. 14 Issue 18, p2797 

    Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan. Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable cases are relatively uncommon because of hepatic function reserve and/or an...

  • Current Targets for Anticancer Drug Discovery. N-H. Nam; K. Parang // Current Drug Targets;Feb2003, Vol. 4 Issue 2, p159 

    The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the...

  • Celebrating novel cancer drugs. Weiss, Robin A // British Journal of Cancer;8/4/2003, Vol. 89 Issue 3, p425 

    Editorial. Focuses on cancer drug development in Great Britain. Progress and development made in cancer drugs; Development of novel means of measuring efficacy, pharmacokinetics and pharmacodynamics of the drugs in action.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics